More than 70 percent of Japanese renal cell carcinoma patients have a specific genetic mutation pattern that is rarely found ...

Data from Phase 1b dose escalation and expansion trial (n=69) shows a favorable safety profile, with manageable adverse events consistent with ...

Many people with cancer can benefit from a second medical opinion. Those with advanced renal cell carcinoma (RCC), who are likely considering multiple treatment options, if not combinations of ...

A new analysis of U.S. military personnel included Black, White, and Hispanic adults newly diagnosed with primary stage I-III RCC between 1998 and 2014. Hispanic and White patients had similar rates ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that more than 40 clinical studies of its oncology portfolio will be presented at the 2026 American Society of Clinical Oncology (ASCO) ...

For patients with primary localized renal cell carcinoma (RCC), especially those who aren’t good candidates for surgery, noninvasive or minimally invasive ablative treatments have emerged as important ...

In a recent study, mean sensitivity was 85.5% and specificity 87% for detection of clear-cell renal cell carcinoma. (HealthDay News) — ⁸⁹Zr-labeled monoclonal antibody ([⁸⁹Zr]Zr-girentuximab) for ...

Personalized cancer vaccine showed promising results, with all patients cancer-free at nearly three years follow-up. The vaccine targets unique cancer-specific antigens, effectively steering the ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, ...

Evaluating the combined role of HHLA2 and PD-L1 as biomarkers in first-line nivolumab therapy in advanced clear cell renal cell carcinoma. This is an ASCO Meeting Abstract from the 2025 ASCO ...